skip to main content

Durable Mechanical Circulatory Support Devices

Patel, Chetan B ; Rogers, Joseph G

Progress in Cardiovascular Diseases, 2011, Vol.54(2), pp.132-143 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
  • Título:
    Durable Mechanical Circulatory Support Devices
  • Autor: Patel, Chetan B ; Rogers, Joseph G
  • Assuntos: Advanced Heart Failure ; Ventricular Assist Devices ; Mechanical Circulatory Support ; Bridge to Transplant ; Destination Therapy ; Cardial Transplantation ; Medicine
  • É parte de: Progress in Cardiovascular Diseases, 2011, Vol.54(2), pp.132-143
  • Descrição: To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.pcad.2011.06.002 Byline: Chetan B. Patel, Joseph G. Rogers Keywords: Advanced heart failure; Ventricular assist devices; Mechanical circulatory support; Bridge to transplant; Destination therapy; Cardial transplantation Abbreviations: AVM, arteriovenous malformation; BTT, bridge to transplant; DT, destination therapy; FDA, Food and Drug Administration; HMII, HeartMate II; HMW, high molecular weight; ICD, implantable cardiodefibrillator; INR, international normalized ratio; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; QOL, quality of life; RV, right ventricular; UNOS, United Network for Organ Sharing; VAD, ventricular assist device; VT/VF, ventricular tachycardia/ventricular fibrillation; vWF, von Willebrand factor; REMATCH, Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure Abstract: Individuals afflicted with advanced systolic heart failure who have become unresponsive to standard medical and electrical therapies are categorized as having American Heart Association stage D heart failure. The high mortality rates for medically treated stage D heart failure have not improved in the last 10 years, and patients at this advanced stage require either palliative measures or surgical management of heart failure. In recent years, surgically implanted ventricular assist devices (VADs) have become available for long-term use and are now commonly used as a therapy for advanced heart failure. The data generated from this early experience have clearly shown that VADs improve survival and quality of life in patients with advanced heart failure when implanted as a temporary measure or as long-term support. However, with a growing heart failure population, there is much work to be done to continually improve VAD technology, patient selection criteria, and postimplantation management to define the optimal role for assist devices in the management of systolic heart failure. Article Note: (footnote) Statement of Conflict of Interest: see page 141.
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.